An appraisal of recently patented compounds for bladder overactivity and urinary incontinence

Bibliography

• TAKEDA M, ARAKI I, KAMIYAMA M, TAKIHANA Y, KOMURO M, FURUYA Y: Diagnosis and treatment of voiding symptoms. Urology (2003) 62 (5.Supp1.2):11–19.
   Google Scholar
• ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. (2002) 21:167–178.
   PubMed Web of Science ®Google Scholar
• MOSTWIN JL: Pathophysiology: the varieties of bladder overactivity. Urology (2002) 60\(Supp1.5A):22–27.
   Google Scholar
• WEIN AJ: Diagnosis and treatment of the overactive bladder. Urology (2003) 62(5.Supp1.2):20–27.
   Google Scholar
• HUNSKAAS, LOSE G, SYKES D, VOSS S: The prevalence of UI in women in four European countries. Br . J Urol. Int. (2004) 93:324–330.
   Google Scholar
• MINASSIAN VA, DRUTZ HP, AL-BADR A: UI as a worldwide problem. Int.j Cynaecol Obstet. (2003) 82(3):327–338.
   PubMed Web of Science ®Google Scholar
• ABRAMS P: Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology (2003) 62 (Supp1.5B):28–37.
   Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World j Urol. (2003) 20:327–336.
   PubMed Web of Science ®Google Scholar
• MOLLER LA, LOSE G, JORGENSEN T: The prevalence and bothersomeness of lower urinary tract symptoms in women 40-60 years of age. Acta Obstet. Cynecol Scand. (2000) 79(4):298–305.
   PubMed Web of Science ®Google Scholar
• UEDA T, TAMAKI M, KAGEYAMA S, YOSHIMURA N, YOSHIDA 0: UI among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. hat. Urol (2000) 7(3):95–103.
   Web of Science ®Google Scholar
• THOM D: Variation in estimates of UI prevalence in the community: effects of differences in definition, population characteristics, and study type. Am . Ceriatr: Soc. (1998) 46(4):473–480.
   PubMed Web of Science ®Google Scholar
• HUNSKAARS, BURGIO K, DIOKNO A, HERZOG AR, HJALMAS K, LAPITAN MC: Epidemiology and natural history of UI in women. Urology (2003) 62 (Supp1.4A):16–23.
   Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br.j Urol. Int. (2001) 87:760–766.
   Google Scholar
• HAY-SMITH J, HERBISON P, ELLIS G, MOORE K: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Library (2004):1. (Cochrane Review).
   Google Scholar
• HERBISON P, HAY-SMITH J, ELLIS G, MOORE K: Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br. Med. (2003) 326:1–7.
   Web of Science ®Google Scholar
• ANDERSSON KE, YOSHIDA M: Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur. Urol. (2003) 43(1):1–5.
   Web of Science ®Google Scholar
• BRADING AF: The physiology of the mammalian urinary outflow tract. Exp. Physiol (1999) 84(1):215–221.
   PubMed Web of Science ®Google Scholar
• VAUGHAN CW, SATCHELL PM: Urine storage mechanisms. Progr. Neurobiol (1994) 46:215–237.
   Web of Science ®Google Scholar
• DE GROAT WC, YOSHIMURA N: Pharmacology of the lower urinary tract. Ann. Rev Pharmacol Toxicol (2001) 41:691–721.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of the pharmacology ofthe bladder.
   Google Scholar
• GABELLA G, DAVIS C: Distribution of afferent axons in the bladder of rats. Neurocytol (1998) 27(3):141–155.
   PubMedGoogle Scholar
• HEDGE SS, EGLEN RM: Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. (1999) 64:419–442.
   PubMed Web of Science ®Google Scholar
• D'AGOSTINO G, BOLOGNESI ML, LUCCHELLI A et al.: Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptorsubtype. Br. Pharmacol (2000) 129(3):493–500.
   Google Scholar
• CHESS-WILLIAMS R, CHAPPLE CR, YAMANISHI T, YASUDA K, SELLERS DJ: The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.' Auton. Pharmacol (2001) 21:243–248.
   PubMedGoogle Scholar
• FETSCHER C, FLEICHMAN M, SCHMIDT M, KREGE S, MICHEL MC: M3 muscarinic receptors mediate contraction of human urinary bladder. Br. Pharmacol (2002) 136(5):641–643.
   PubMed Web of Science ®Google Scholar
• CAUFIELD MP, BIRDSALL NJ: International Union of Pharmacology XVII: classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 50(2):279–290.
   PubMed Web of Science ®Google Scholar
• SIGALA S, MIRABELLA G, PERONI A et al.: Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology (2002) 60:719–725.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI 0, SHISHIDO K, TAMURA K et al.: Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. Urol. (1996) 156:1208–1213.
   Google Scholar
• EGLEN RM, CHOPPIN A, WATSON N: Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sri. (2001) 22(8):409–414.
   PubMed Web of Science ®Google Scholar
• HEDGE SS, CHOPPIN A, BONHAUS D et al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. Pharmacol (1997) 120(8):1409–1418.
   PubMed Web of Science ®Google Scholar
• DANIELS DV, MELOY TD, LOURY DN et al.: Functional pharmacological characterization of the muscarinic cholinoceptor-mediated inhibition of adenylyl cyclase in primary cultured human bladder detrusor smooth muscle cells. Life Sci. (1999) 64:590.
   Web of Science ®Google Scholar
• SOMOGYI GT, DE GROAT WC: Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sri. (1999) 64(6-7):411–418.
   PubMed Web of Science ®Google Scholar
• ALBERTS P: Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretions in the guinea pig urinary bladder in vitro. I Pharmacol Exp. Ther. (1995) 274:1458–1468.
   Web of Science ®Google Scholar
• D'AGOSTINO G, BARBIERI A, CHIOSSA E, TONINI M: M4 muscarinic autoreceptor-mediated inhibition of [3H]acetylcholine release in the rat isolated urinary bladder. I Pharmacol Exp. Ther. (1997) 283(2):750–756.
   PubMed Web of Science ®Google Scholar
• MICHELOTTI GA, PRICE DT, SCHWINN DA: al-Adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther (2000) 88(3):281–309.
   PubMed Web of Science ®Google Scholar
• GOEPEL M, WITTMANN A, RUBBEN H, MICHEL M: Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Um] Res. (1997) 25(3):199–206.
   Google Scholar
• MICHEL MC: Potential role of aradrenoceptors in the aetiology of LUTS. Eur: Um] Sapp] (2002) 1:5–13.
   Google Scholar
• MALLOY BJ, PRICE DT, PRICE RR et al: arAdrenergic receptor subtypes in human detrusor. Um] (1998) 160(3):937–943.
   Google Scholar
• SOMOGYI GT, TANOWITZ M, DE GROAT WC: Prejunctional facilitatory aradrenoceptors in the rat urinary bladder. Br. PharmacoL (1995) 114:1710–1716.
   PubMed Web of Science ®Google Scholar
• JEONG MS, LEE JG: The role of spinal and peripheral al- and a2-adrenoceptors on bladder activity induced by bladder distension in anaesthetised rat. Br. J. Um] hat. (2000) 85(7):925–931.
   Google Scholar
• TAKEDA M, OBARA K, MIZUSAKA T et al.: Evidence for I33-adrenoceptor subtypes in relaxation of the urinary bladder detrusor: analysis by molecular biological and pharmacological methods. I Pharmacol Exp. Thec (1999) 288:1367–1373.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Pharmacology of the lower urinary tract smooth muscle and penile erectile tissues. Pharmacol Rev (1993) 45:253–230.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI 0: I33-Adrenoceptors in human detrusor muscle. Urology (2002) 59(Suppl. 5A):25–29.
   Google Scholar
• IGAWA Y, YAMAZAKI Y, TAKEDA H et al.: Functional and molecular biological evidence for a possible 133 adrenoceptor in the human detrusor muscle. Br. Pharmacol (1999) 126:819–825.
   PubMed Web of Science ®Google Scholar
• RAYMOND JR, MUKHIN YV, GELASCO A et al: Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther. (2001) 92(2-3):179–212.
   PubMed Web of Science ®Google Scholar
• TONINI M, MESSORI E, FRANCES CHETTI GP et al.: Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br. J. Pharmacol (1994) 113(1):1–2.
   Google Scholar
• D'AGOSTINO G, CONDINO A, FRANCESCHETTI GP, CANDURA SM, TONINI M: Prejunctional 5-HT4 receptors enhance tritiated acetylcholine release from electrically-stimulated human detrusor strips. Pharmacol Res. (2001) 43 (Suppl. A):124.
   Google Scholar
• SEVERINI C, IMPROTA G, FALCONIERI-ERSPAMER G, SALVADORI S, ERSPAMER V: The tachykinin peptide family. Pharmacol Rev (2002) 54(2):285–322.
   PubMed Web of Science ®Google Scholar
• BURCHER E, ZENG XP, STRIGAS J, SHANG F, MILLARD RJ, MOORE KH: Autoradiographic localisation of tachykinin and calcitonin gene-related peptide receptors in adult urinary bladder. Um] (2000) 163(1):331–337.
   Google Scholar
• SMET PJ, MOORE KH, JONAVICIUS J: Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab. Invest. (1997) 77(1):37–49.
   PubMed Web of Science ®Google Scholar
• BOSELLI C, GOVONI S, CONDINO AM, D'AGOSTINO G: Bladder instability: a re-appraisal of classical experimental approaches and development of new therapeutic strategies. Amon. Pharmacol (2001) 21(5-6):219–229.
   Google Scholar
• NORTH RA: Molecular physiology of P2X receptors. Physiol Rev (2002) 82:1013–1067.
   PubMed Web of Science ®Google Scholar
• DUNN PM, ZHONG Y, BURNSTOCK G: P2X receptors in peripheral neurons. Frog. Neumbiol (2001) 65:107–134.
   Google Scholar
• MOORE KH, RAY RR, BARDEN JA: Loss of purinergic P2X3 and P2X5 receptor innervation in human detrusor from adults with urge incontinence. Neurosci. (2001) 21(RC166):1–6.
   Google Scholar
• O'REILLY BA, KOSAKA AH, CHANG TK, FORD AP, POPERT R, MCMAHON SB: A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. Br. Um] Int. (2001) 87(7):617–622.
   Web of Science ®Google Scholar
• JAGGAR JH, PORTER VA, LEDERER VJ, NELSON MT: Calcium sparks in smooth muscle. Am. j Physiol Physiol (2000) 278:C235–C256.
   Web of Science ®Google Scholar
• SEINO S: ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Ann. Rev Physiol (1999) 61:337–362.
   PubMed Web of Science ®Google Scholar
• COETZEE WA, AMARILLO Y, CHIU J et al.: Molecular diversity of K+ channels. Ann. NY Acad. Sci. (1999) 868:233–285.
   PubMed Web of Science ®Google Scholar
• SHIEH CC, COGHLAN M, SULLIVAN JP: Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev (2000) 52:557–594.
   PubMed Web of Science ®Google Scholar
• COGHLAN MJ, CARROLL WA, GOPALAKRISHNAN M: Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. I Med. Chem. (2001) 44(11):1627–1653.
   PubMed Web of Science ®Google Scholar
• BUCKNER SA, MILICIC I, DAZA AV et al.: Pharmacological and molecular analysis of ATP-sensitive K+ channels in the pig and human detrusor. Eur. .1 Pharmacol (2000) 400(2–3):287–295.
   Google Scholar
• KARICHETI V, CHRIST GJ: Physiological roles for K+ channels and gap junctions in urogenital smooth muscle: implications for improved understanding of urogenital function, disease and therapy. Curr. Drug Targets ( 2001) 2(1):1–20.
   PubMed Web of Science ®Google Scholar
• BUCKNER SA, MILICIC I, DAZA AV, COGHLAN MJ, GOPALAKRISHNAN M: Spontaneous phasic activity of the pig urinary bladder smooth muscle: characteristics and sensitivity to potassium channel modulators. Br. I Pharmacol (2002) 135(3):639–648.
   PubMed Web of Science ®Google Scholar
• BLOK BFM, WILLEMSEN AT, HOLSTEGE G: A PET study on brain control of micturition in humans. Brain (1997) 120:111–121.
   PubMed Web of Science ®Google Scholar
• YAN Z: Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol Neurobiol (2002) 26(2-3):203–216.
   PubMed Web of Science ®Google Scholar
• SMITH MS, SCHAMBRA UB, WILSON KH, PAGE SO, SCHVVINN DA: al-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding aradrenergic receptor subtypes at four distinct levels. Ma Brain Res. (1999) 63(2):254–261.
   Web of Science ®Google Scholar
• SMITH MS, SCHAMBRA UB, WILSON KH et al.: a2-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding a2-adrenergic receptor subtypes at four distinct levels. Brain Res. Ma Brain Res. (1995) 34(1):109–111.
   PubMedGoogle Scholar
• KONTANI H, TSUJI T, KIMURA S: Effects of adrenergic a2-receptor agonists on urinary bladder contraction in conscious rats. fpn. Pharmacol (2000) 84(4):381–390.
   Web of Science ®Google Scholar
• ISHIZUKA 0, PERSSON K, MATTIASSON A, NAYLOR AM, WYLLIE MG, ANDERSSON KE: Micturition in conscious rats with and without bladder outlet obstruction: role of spinal aradrenoceptors. Br. Pharmacol (1996) 117:962–966.
   PubMed Web of Science ®Google Scholar
• ESPEY MJ, DU HJ, DOWNIE JW: Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res. (1998) 798(1-2):101–108.
   PubMed Web of Science ®Google Scholar
• BURGARD EC, FRASER MO, THOR KB: Serotonergic modulation of bladder afferent pathways. Urology (2003) 62(Suppl. 4A):10–15.
   Google Scholar
• DE GROAT WC: Influence of central serotonergic mechanisms on lower urinary tract function. Urology (2002) 59(5.Supp1.1):30–36.
   Google Scholar
• •A mini review on 5-HT receptors distribution and functions regulating lower urinary tract.
   Google Scholar
• GOBERT A, LEJEUNE F, RIVET JM, AUDINOT V, NEWMAN -TANCREDI A, MILLAN MJ: Modulation of the activity of central serotoninergic neurons by novel serotonin 1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.' Pharinacol Exp. Ther. (1995) 273(3):1032–1046.
   Google Scholar
• HELTON L, THOR KB, BAEZ M: 5-Hydroxytryptamine 2A, 5-hydroxytryptamine 2B and 5-hydroxytryptamine 2C receptor mRNA expression in the spinal cord of rat, cat, monkey, and human. Neuroreport (1995) 5:2617–2620.
   Web of Science ®Google Scholar
• ANDREE B, HEDMAN A, THORBERG SO, NILSSON D, HALLDIN C, FARDE L: Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (2003) 167(1):37–45.
   PubMed Web of Science ®Google Scholar
• THOR KB, NICKOLAUS S, HELKE CJ: Autoradiographic localization of 5-hydroxytryptamine1p, 5-hydroxytryptamine1g and 5-hydroxytryptamine1c/2 binding sites in the rat spinal cord. Neuroscience (1993) 55:235–252.
   PubMed Web of Science ®Google Scholar
• DANUSER H, THOR KB: Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br. Pliannacol. (1996) 118(1):150–154.
   Google Scholar
• KID EJ, LAPORTE AM, LANGLOIS Z et al.: 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res. (1993) 612:289–293.
   PubMed Web of Science ®Google Scholar
• KAKIZAKI H, YOSHIYAMA M, KOYANAGI T et al: Effects of WAY100635, a selective 5-HT1A-receptor antagonist on the micturition-reflex pathway in the rat. Am . J. Physiol (2001) 280:R1407–R1413.
   Google Scholar
• PENG YB, WU J, WILLIS WD, KENSHALO DR: GABA(A) and 5-HT3 recptors are involved in dorsal root reflexes: possible role in periaqueductal gray descending inhibition. .1. Neurophysiol (2001) 86(1):49–58.
   Google Scholar
• CHAIKIN DC, BLAIVAS JG: Voiding dysfunction : definitions. Can: Opin. Um]. (2001) 11:395–398.
   PubMedGoogle Scholar
• SCHUMACHER S: When is a urodynamic investigation indicated for overactive bladder? Urologe A (2003) 42(6):801–806.
   PubMedGoogle Scholar
• BRADING AF: A myogenic basis for the overacting bladder. Urology (1997) 50\(Supp1.6A):57–69.
   Google Scholar
• DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50\(Supp1.6A):36–52.
   Google Scholar
• YOSHIDA M, HOMMA Y, INADOME A et al.: Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp . Gerontol (2001) 36(1):99–109.
   PubMed Web of Science ®Google Scholar
• HARRISON SC, HUNNAM GR, FARMAN P, FERGUSON DR, DOYLE PT: Bladder instability and denervation in patients with bladder outflow obstruction. Br. I Urol. (1987) 60(6):519–522.
   PubMedGoogle Scholar
• MILLS IW, GEENLAND JE, MCMURRAY G et al: Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J. Urol. (2000) 163(2):646–651.
   PubMed Web of Science ®Google Scholar
• FRY CH, SKENNERTON D, WOOD D, WU C: The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urology (2002) 59(5Supp1.1):3–12.
   Google Scholar
• PONTARI MA, BRAVERMAN AS, RUGGIERI SR MR: The M2 muscarinic receptor mediates in-vitro bladder contractions from patients with neurogenic bladder dysfunction. Am. I Physic] Regal Integr. Comp. Physic] E -pub (29/01/2004).
   Google Scholar
• CHESS-WILLIAMS R: Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid. Pharmacol (2002) 22(3):133–145.
   PubMedGoogle Scholar
• •A comprehensive review of muscarinic receptor distribution in the lower urinary tract. so . SERELS S, STEIN M: Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn. (1998) 17(1):31–36.
   Google Scholar
• BLUE DR, DANIELS DV, GEVER JR et al.: Pharmacological characteristics of Ro115-1240, a selective alA/1L-adrenoceptor partial agonist: a potential therapy for stress UI. Br. .1. Urol. Int. (2004) 93(1):162–170.
   Google Scholar
• LEPOR H, THEUNE C: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. Urol. (1995) 154(1):116–118.
   Web of Science ®Google Scholar
• BUZELIN JM, FONTEYNE E, KONTTURI M, WITJES WP, KHAN A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br.j Urol. (1997) 80(4):597–605.
   PubMedGoogle Scholar
• LEPOR H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology (1998) 51(6):892–900.
   PubMed Web of Science ®Google Scholar
• SULLIVAN J, ABRAMS P: a -Adrenoceptor antagonists in neurogenic lower urinary tract dysfunction. Urology (1999) 53(3.Supp1.3a):21–27.
   Google Scholar
• KAKIZAKI H, KOYANAGI T: Current view and status of the treatment of lower urinary tract symptoms and neurogenic lower urinary tract dysfunction. Br. I Ural Int. (2000) 85 (Supp1.2):25–30.
   Google Scholar
• FITZPATRICK JM: Facts and future lines of research in lower urinary tract symptoms in men and women: an overview of the role of aradrenoreceptor antagonists. Br. J. Urol. Int. (2000) 85\(Supp1.2):1–5.
   Google Scholar
• YAMAMOTO T, GHOSH R, DE GROAT WC, SOMOGYI GT: Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via aradrenoceptors. Eur. Pharmacol (2001) 414(1):31–35.
   PubMed Web of Science ®Google Scholar
• HAMPEL C, DOLBER PC, SMITH MP et al.: Modulation of bladder aradrenergic receptor subtype expression by bladder outlet obstruction. Urol. (2002) 167(3):1513–1521.
   Web of Science ®Google Scholar
• SCHWINN DA, MICHELOTTI GA: al-Adrenergic receptors in the lower urinary tract and vascular bed: potential role for the aiD subtype in filling symptoms and effects of ageing on vascular expression. Br. Urol. Int. (2000) 85 (Supp1.2):6–11.
   Google Scholar
• LECCI A, GIULIANI S, MEINI S, MAGGI CA: Nociceptin and the micturition reflex . Peptides (2000) 21(7):1007–1021.
   PubMed Web of Science ®Google Scholar
• LECCI A, MAGGI CA: Tachyldnins as modulators of the micturition reflex in the central and peripheral nervous system. Regal Pept. (2001) 101(1-3):1–18.
   PubMedGoogle Scholar
• IGAWA Y, SATOH T, MIZUSAWA H et al.: The role of capsaicin-sensitive afferents in autonomic dysreflexia in patients with spinal cord injury. Br. I Urol. Int. (2003) 91(7):637–641.
   Web of Science ®Google Scholar
• MOORE KH, LAM DS, LYNCH W: The tachykinin NK-2 receptor antagonist 5R48968 does not block noncholinergic contractions in unstable human bladder. Peptides (2002) 23(6):1155–1160.
   PubMed Web of Science ®Google Scholar
• RAY FR, MOORE KH, HANSEN MA, BARDEN JA: Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell Tissue Res. (2003) 314(3):351–359.
   PubMed Web of Science ®Google Scholar
• DUTTON JL, HANSEN MA, BAL CAR VJ, BARDEN JA, BENNETT MR: Development of P2X receptor clusters on smooth muscle cells in relation to nerve varicosities in the rat urinary bladder. Neurocytol (1999) 28 (1):4–16.
   PubMedGoogle Scholar
• TAGLIANI M, CANDURA SM, DI NUCCI A et al: A re-appraisal of the nature of the atropine-resistant contraction to electrical field stimulation in the human isolated detrusor muscle. Naunyn Schiniedebergs Arch. Pharinacol (1997) 356(6):750–755. Ha BAYLISS M, WU C, NEWGREEN D, MUNDY ADRENOCEPTOR, FRY CH: A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. Um] (1999) 162:1833–1839.
   Google Scholar
• HARDY LA, HARVEY IJ, CHAMBERS P, GILLESPIE JI: Putative alternatively spliced variant of the P2X1 purinoreceptor in human bladder. Exp. Physiol (2000) 85(4):461–463.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, HEDLUND P: Pharmacologic perspective on the physiology of the lower urinary tract. Urology (2002) 60 (5.Supp1.1):13–20.
   Google Scholar
• GUAY DR: Clinical phannacokinetics of drugs used to treat urge incontinence. Clin. Pharinacokinet. (2003) 42(14):1243–1285.
   PubMed Web of Science ®Google Scholar
• HILLS CJ, WINTER SA, BALFOUR JA: Tolterodine. Drugs (1998) 55(6):813–820.
   PubMed Web of Science ®Google Scholar
• NILVEBRANT L: Clinical experiences with tolterodine. Life Sci. (2001) 68(22-23):2549–2556.
   PubMed Web of Science ®Google Scholar
• MALONE-LEE JG, WALSH JB, MAUGOURD MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. Am. Ceriatr. Soc. (2001) 49(6):700–705.
   PubMed Web of Science ®Google Scholar
• GARELY AD, BURROWS LJ: Current pharmacotherapeutic strategies for overactive bladder. Expert Opin. Pharmacother (2002) 3(7):827–833.
   PubMedGoogle Scholar
• DMOCHOWSKI RR, APPELL RA: Advancements in pharmacologic management of the overactive bladder. Urology (2000) 56 (Supp1.6A):41–49.
   Google Scholar
• ROVNER ES, WEIN AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur. Urol. (2002) 41(1):6–14.
   PubMed Web of Science ®Google Scholar
• GUPTA S, SATHYAN G, MORI T: New perspectives on the overactive bladder: pharmacokinetics and bioavailability. Urology (2002) 60 (5.Supp1.1):78–80.
   Google Scholar
• DIOKNO AC, APPELL RA, SAND PK et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo. Clin. Proc. (2003) 78(6):687–695.
   PubMed Web of Science ®Google Scholar
• FUSGEN I, HAURI D: Trospium chloride: an effective option for medical treatment of bladder overactivity. Int. .1. Clin. Pharmacol Thee: (2000) 38(5):223–234.
   Google Scholar
• LOPEZ PEREIRA P, MIGUELEZ C, CAFFARATI J, ESTORNELL F, ANGUERA A: Trospium chloride for the treatment of detrusor instability in children. .1. Urol (2003) 170(5):1978–1981.
   Google Scholar
• HALASKA M, RALPH G, WIEDEMANN A et al.: Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. Worldj Um] (2003) 20(6):392–399.
   PubMed Web of Science ®Google Scholar
• PAK RW, PETROU SP, STASKIN DR: Trospium chloride: a quaternary amine with unique pharmacologic properties. Cure: Um] Rep. (2003) 4(6)436–440.
   Google Scholar
• IKEDA K, KOBAYASHI S, SUZUKI M et al.: M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharmacol (2002) 366(2):97–103.
   PubMed Web of Science ®Google Scholar
• HATANAKA T, UKAI M, OHTAKE A et al.: In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. International Continence Society Meeting, Florence, Italy (2003). (Abstract 312).
   Google Scholar
• KOBAYASHI S, IKEDA K, MIYATA K: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci. (2004) 74(7):843–853.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, RECHBERGER T, AL-SHUKRI S: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br. Um] Int. (2004) 93(3):303–310.
   Web of Science ®Google Scholar
• MIYAMAE K, YOSHIDA M, MURAKAMI S et al.: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology (2003) 69(4):205–211.
   PubMed Web of Science ®Google Scholar
• CARDOZO L, PRESCOTT K, SERDAREVIC D, SKILLERN L: Can medication prolong warning time? Proceeding International Contincence Society Meeting, Florence, Italy (2003).
   Google Scholar
• KERBUSCH T, MILLIGAN PA, KARLSSON MO: Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br. I Clin. Pharmacol (2004) 57(2):170–180.
   PubMed Web of Science ®Google Scholar
• TESTA R, GUARNERI L, ANGELICO P et al.: Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats. Br.j Urol. Int. (2001) 87(3):256–264.
   Google Scholar
• PEHRSON R, OJTEG G, ISHIZUKA 0, ANDERSSON KE: Effects of NAD-299, a new, highly selective 5-HTIA receptor antagonist, on bladder function in rats. Naunyn Scluniedebergs Arch. Pharmacol. (2002) 366(6):528–536.
   PubMed Web of Science ®Google Scholar
• KHALED SM, ELHILALI M: Role of 5-HT receptors in treatment of overactive bladder. Drugs Today (2003) 39(8):599–607.
   PubMed Web of Science ®Google Scholar
• MILLARD RJ, MOORE K, RENCKEN R, YALCIN I, BUMP RC: Duloxetine versus placebo in the treatment of stress UI: a four-continent randomized clinical trial. Br. I Urol. hat. (2004) 93(3):311–318.
   Web of Science ®Google Scholar
• READ KE, SANGER GJ, RAMAGE AG: Evidence for the involvement of central 5-HT7 receptors in the micturition reflex in anaesthetized female rats. Br. .1. Pharmacol. (2003) 140(1):53–60.
   Google Scholar
• ISHIZUKA 0, GU B, IGAWA Y, NISHIZAWA 0, PEHRSON R, ANDERSSON KE: Role of supraspinal serotonin receptors for micturition in normal conscious rats. Neurourol. Urodyn. (2002) 21(3):225–230.
   PubMed Web of Science ®Google Scholar
• MESSORI E, RIZZI CA, CANDURA SM, LUCCHELLI A, BALESTRA B, TONINI M: 5-Hydroxytryptamine receptors that facilitate excitatory neuromuscular transmission in the guinea-pig isolated detrusor muscle. Br. Pharmacol. (1995) 115(4):677–683.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, RADLEY SC, MARTIN SW SELLERS DJ, CHESS -WILLIAMS R: Serotonin-induced potentiation of cholinergic responses to electrical field stimulation in normal and neurogenic overactive human detrusor muscle. Br. Urol. hat (2004) 93(4):599–604.
   Web of Science ®Google Scholar
• •A recent analysis of 5-HT4 receptors activity in normal and neurogenic human bladder.
   Google Scholar
• WEIN AJ: Pharmacological agents for the treatment of UI due to overactive bladder. Expert Opin. Invectig. Drugs (2001) 10(1):65–83.
   PubMed Web of Science ®Google Scholar
• MICHEL MC, BRIONI JD: m meeting report for the ASPET Ray Fuller Symposium: lower urinary tract disorders: physiology, pharmacology, and therapeutic approaches. Phannacol . Exp. The]: (2002) 303(1):431–437.
   PubMedGoogle Scholar
• •An interesting report focused on the state of art of aetiology of lower urinary tract disorders.
   Google Scholar